News
CSLLY
24.74
-2.83%
-0.72
Top and lowest-rated large-cap stocks heading into earnings
Seeking Alpha · 3d ago
Weekly Report: what happened at CSLLY last week (0406-0410)?
Weekly Report · 3d ago
Ord Minnett Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 3d ago
BUZZ-Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'
Reuters · 3d ago
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 6d ago
Bell Potter Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 04/09 01:37
BUZZ-Citi sees strong quarterly growth with likely cost impact for Resmed
Reuters · 04/08 19:29
BUZZ-Australia's CSL gains on US tariff relief on key product imports
Reuters · 04/07 02:40
BRIEF-CSL Notes Announcement By United States Administration On 2 April
Reuters · 04/07 02:10
Weekly Report: what happened at CSLLY last week (0330-0403)?
Weekly Report · 04/06 10:13
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Seeking Alpha · 03/30 13:17
Weekly Report: what happened at CSLLY last week (0323-0327)?
Weekly Report · 03/30 10:13
UPDATE 2-Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
Reuters · 03/29 11:49
Weekly Report: what happened at CSLLY last week (0316-0320)?
Weekly Report · 03/23 10:10
Weekly Report: what happened at CSLLY last week (0309-0313)?
Weekly Report · 03/16 10:10
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Seeking Alpha · 03/14 14:35
KalVista Pharmaceuticals: Has Potential But With Caveats
Seeking Alpha · 03/12 15:07
Jarden Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 03/12 00:45
Morgans Keeps Their Buy Rating on CSL (CMXHF)
TipRanks · 03/11 00:15
CSL to invest USD 1.5 billion to expand Kankakee, Illinois plasma therapy plant
Reuters · 03/09 15:01
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.